1 year. Secondary outcomes were determined by Kaplan-Meier analyses.Results: This study included 107 FEVAR patients that were predominantly treated for juxtarenal aneurysm repair (90.7%) and 40 BEVAR patients that were mostly treated for repair of thoracoabdominal aneurysms (90.0%). From these, 90 FEVAR and 26 BEVAR patients were included for imaging analysis ($2 postoperative computed tomography angiographies [CTAs]). Following FEVAR, aneurysm sac volumes decreased significantly up to 24 months and remained constant thereafter, whereas aneurysm sac volumes after BEVAR did not change significantly over time (Fig 1). At last imaging follow-up, 68.9% of FEVAR treated aneurysms showed >5% shrinkage vs 29.8% after BEVAR (P < .001). FEVAR patients had higher freedom from aneurysm-related complications (3-year: FEVAR: 0.65.7%; 95% CI, 55.7%-77.6% vs BEVAR: 51.4%; 95% CI, 32.5%-81.4%; log-rank P ¼ .035) and showed higher freedom from secondary interventions (FEVAR: 84.6%; 95% CI, 77.1%-93.0% vs BEVAR: 74.8%; 95% CI, 60.9%-91.9%; log-rank P ¼ .034). However, among groups, there was no difference in freedom from endoleaks type I/III (3-year: FEVAR, 89.9%; 95% CI, 83.7%-96.6% vs BEVAR, 80.0%; 95% CI, 64.5%-99.4%; log-rank P ¼ .13). Finally, early aneurysm sac shrinkage showed significant higher freedom from the composite outcome (log-rank P ¼ .022) (Fig 2).Conclusions: Initial sac regression at 1 year is significantly associated with improved clinical outcomes; freedom from aneurysm-related complications. Both BEVAR and FEVAR need secondary interventions in the first year to maintain clinical success. The proportion of patients with sac regression after BEVAR is lower compared with FEVAR, and therefore will probably require more intensified surveillance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.